Company / FCF Margin
BioNexus Gene Lab Corp FCF Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-25.3%
FY2025
5-year range
-25.3% / 5.1%
FY2021-FY2025
Trend
-3.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has declined for 3 consecutive years, from 5.1% in FY2022 to -25.3% in FY2025.
Based on SEC 10-K filings.
-25.3% in FY2025 with a 5-year CAGR of -26.4%.
Declined from -20.2% to -25.3% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -30.3pp
- 5-Year Change
- -26.4pp
- 10-Year Change
- -
Key checks
Key Insights
- BioNexus Gene Lab Corp's fcf margin has declined for 3 consecutive years.
- In FY2025, fcf margin decreased 3.5% year-over-year.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -25.3% | -3.5% |
| FY2024 | -24.4% | -20.9% |
| FY2023 | -20.2% | -499.6% |
| FY2022 | 5.1% | +12525.0% |
| FY2021 | 0.0% | -96.5% |
| FY2020 | 1.1% | +100.6% |
| FY2019 | -181.2% | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026